Ebola outbreaks occur in areas where many people are living with HIV; however, there is very little evidence on how people with HIV respond to Ebola vaccines. In this edition of the podcast, we talk to authors of a study assessing the safety and immunogenicity of an Ebola vaccine in people with well controlled HIV.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Lancet Group. Innehållet i podden är skapat av The Lancet Group och inte av,
eller tillsammans med, Poddtoppen.
